Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)
Trial details
- Registry ID
- NCT07868939
- Drugs studied
- VK2735 Oral
TrialRedline tracks 8 clinical trials sponsored by Viking Therapeutics, Inc.: 4 Phase 3, 4 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)NCT07868939 | VK2735 Oral | Recruiting | 2028-10Estimated |
| Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)NCT07868835 | VK2735 | Recruiting | 2028-07Estimated |
| VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)NCT07104383 | VK2735 | Active not recruiting | 2027-07-01Estimated |
| VK2735 for Weight Management Phase 3NCT07104500 | VK2735 | Active not recruiting | 2027-07-01Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| VK2735 for Weight Management Phase 2 (Venture Oral Dosing)NCT06828055 | VK2735 | Completed | 2025-06-24Actual |
| VK2735 for Weight Management Phase 2NCT06068946 | VK2735 | Completed | 2024-02-27Actual |
| A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASHNCT04173065 | Placebos, VK2809 | Completed | 2023-05-15Actual |
| Acute Hip Fracture Study in Patients 65 Years or GreaterNCT02578095 | VK5211 | Completed | 2017-11-15Actual |
Names as written in the registry records.
NCT07868835 · Viking Therapeutics, Inc.
Before: Not yet recruiting. After: Recruiting.
NCT07868939 · Viking Therapeutics, Inc.
Before: Not yet recruiting. After: Recruiting.
NCT07868939 · Viking Therapeutics, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily Description: To demonstrate that VK2735 27.5mg, 35mg, and 55mg daily oral (each dose separately) is superior to placebo for percent change in body weight from baseline to week 68 Time frame: 68 weeks. After: Measure: Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily Description: To demonstrate that VK2735 daily oral is superior to placebo for percent change in body weight from baseline to week 68 Time frame: 68 weeks.
NCT07868835 · Viking Therapeutics, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Percentage change in body weight for participants receiving VK2735 orally once daily Description: To demonstrate that VK2735 27.5mg, 35mg, and 55mg daily oral (each dose separately) is superior to placebo for percent change in body weight from baseline to week 68 Time frame: 68 weeks. After: Measure: Percentage change in body weight for participants receiving VK2735 orally once daily Description: To demonstrate that VK2735 daily oral is superior to placebo for percent change in body weight from baseline to week 68 Time frame: 68 weeks.
NCT07104383 · Viking Therapeutics, Inc.
Before: Recruiting. After: Active not recruiting.
NCT02578095 · Viking Therapeutics, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Efficacy in hip fracture patients confirmed by DXA scan.. After: Measure: Efficacy in Hip Fracture Patients Confirmed by DXA Scan..
NCT07104500 · Viking Therapeutics, Inc.
Before: Recruiting. After: Active not recruiting.